Ying William, Levons Jaquan K, Carney Andrea, Gandhi Rajesh, Vydra Vicky, Rubin A Erik
Bristol-Myers Squibb, Drug Product Science & Technology, New Brunswick, NJ, USA.
Bristol-Myers Squibb, Drug Product Science & Technology, New Brunswick, NJ, USA
J Lab Autom. 2016 Jun;21(3):378-86. doi: 10.1177/2211068215585484. Epub 2015 May 12.
A novel semiautomated buffer exchange process workflow was developed to enable efficient early protein formulation screening. An antibody fragment protein, BMSdab, was used to demonstrate the workflow. The process afforded 60% to 80% cycle time and scientist time savings and significant material efficiencies. These efficiencies ultimately facilitated execution of this stability work earlier in the drug development process, allowing this tool to inform the developability of potential candidates for development from a formulation perspective. To overcome the key technical challenges, the protein solution was buffer-exchanged by centrifuge filtration into formulations for stability screening in a 96-well plate with an ultrafiltration membrane, leveraging automated liquid handling and acoustic volume measurements to allow several cycles of exchanges. The formulations were transferred into a vacuum manifold and sterile filtered into a rack holding 96 glass vials. The vials were sealed with a capmat of individual caps and placed in stability stations. Stability of the samples prepared by this process and by the standard process was demonstrated to be comparable. This process enabled screening a number of formulations of a protein at an early pharmaceutical development stage with a short sample preparation time.
开发了一种新型半自动缓冲液交换工艺工作流程,以实现高效的早期蛋白质制剂筛选。使用抗体片段蛋白BMSdab来演示该工作流程。该工艺可节省60%至80%的循环时间和科研人员时间,并显著提高材料效率。这些效率最终有助于在药物开发过程中更早地开展稳定性研究工作,使该工具能够从制剂角度为潜在开发候选药物的可开发性提供参考。为克服关键技术挑战,利用自动液体处理和声学体积测量技术,通过离心过滤将蛋白质溶液缓冲液交换到96孔板中的制剂中,以便使用超滤膜进行稳定性筛选,从而实现多个交换循环。将制剂转移到真空歧管中,无菌过滤到装有96个玻璃小瓶的架子中。小瓶用单个瓶盖的帽垫密封,并放置在稳定性试验箱中。结果表明,通过该工艺制备的样品与通过标准工艺制备的样品稳定性相当。该工艺能够在药物研发早期阶段以较短的样品制备时间筛选多种蛋白质制剂。